You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 三葉草生物-B(2197.HK)高開近5% 研究指其新冠疫苗加強劑應對Omicron抗體水平高於三劑阿斯利康疫苗
格隆匯4月21日丨三葉草生物-B(2197.HK)高開近5%,報7.18港元,總市值83億港元。該公司公佈,兩項正在進行的SCB-2019 (CpG 1018/鋁佐劑)評估研究的更多積極數據,顯示在基礎免疫接種後約6個月仍具持久的保護效力,以及接種一劑加強針後,產生了中和Omicron和其他值得關注變異株的強勁免疫。研究顯示,在已接種兩劑阿斯利康新冠疫苗的個體中,接種SCB-2019加強針誘導的針對原型毒株的中和抗體水平,比接種三劑阿斯利康疫苗的個體高出約4倍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account